Showing 4 ideas for tag "emerging"

Goal 2: Reduce Human Disease

Improving the phenotyping of the major (chronic) heart, lung, and blood diseases

Which phenotypic and molecular characteristics predict differential responses to therapy in individuals with chronic heart, lung, blood, and sleep (HLBS) diseases?

Is this idea a Compelling Question (CQ) or Critical Challenge (CC)? Compelling Question (CQ)

Details on the impact of addressing this CQ or CC

• Enable pathophysiologically targeted therapies and prevention
• Enable subgroup assessment of intervention
• Better define gene-gene and gene-environment interactions
• Improve risk stratification
• Understand those who are protected against disease
• Inform development of better in vitro and in vivo models to assess disease and response

Feasibility and challenges of addressing this CQ or CC

Advances in –omics, diagnostics, cell biology, imaging are ready to be applied

Name of idea submitter and other team members who worked on this idea NHLBI Staff

Voting

30 net votes
42 up votes
12 down votes
Active

Goal 2: Reduce Human Disease

Enabling technologies that improve the precision and depth by which we evaluate people

How do we enable technologies that improve the precision and depth by which we evaluate patients to better understand pathophysiology and develop, test and optimize therapy?

 

Use of EHR to understand HLB disease?

Should NHLBI/researchers have a larger role in the development of the EHR?

Is this idea a Compelling Question (CQ) or Critical Challenge (CC)? Compelling Question (CQ)

Details on the impact of addressing this CQ or CC

Generation of more relevant models for accelerating mechanistic and therapeutic studies.

Name of idea submitter and other team members who worked on this idea NHLBI Staff

Voting

5 net votes
16 up votes
11 down votes
Active

Goal 2: Reduce Human Disease

Extending gene editing and iPS/cell technologies to high throughput formats

Can we extend gene editing and iPS/cell technologies to high throughput formats for the evaluation of genetic variants identified from GWAS in the development and progression of disease?

Is this idea a Compelling Question (CQ) or Critical Challenge (CC)? Compelling Question (CQ)

Name of idea submitter and other team members who worked on this idea NHLBI Staff

Voting

-15 net votes
3 up votes
18 down votes
Active